Medical Director The Texas Liver Institute, Clinical Professor of Medicine, University of Texas Health Science Center
Gastroenterology
Dr. Eric J. Lawitz, MD
|
|
Give Review
Doctor Eric J. Lawitz, MD practices Gastroenterology. He attended Rush Medical College. He over the years received 1 awards: "Fellow (AGAF)". Eric Lawitz is also published. He has 82 publications published. The lastest publication: "Utility of preoperative fiberoptic flexible sigmoidoscopy in the evaluation of patients with suspected gynecologic malignancy.' Doctor Eric J. Lawitz, MD is registered with Medicare and accepts Medicare payments.
Publications
- GS-9857 in patients with chronic Hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
- Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
- Interferon-free, direct-acting antiviral therapy for chronic Hepatitis C.
- Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with Hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
- Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
- A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic Hepatitis C virus genotype 4 infection.
- Accuracy of Fibroscan, Compared with Histology, in Analysis of Liver Fibrosis in Patients with Hepatitis B or C: A US Multi-center Study.
- A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.
- Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for Hepatitis C virus genotype...
- Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and Cirrhosis.
- Exploratory Trial of Ombitasvir and ABT-450/r With or Without Ribavirin for HCV Genotype 1, 2, and 3 Infection.
- Clinical and In Vitro Resistance to GS-9669, a Thumb Site II Nonnucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase.
- IP-10 Kinetics in Treatment-Naïve Versus -Experienced Patients Receiving Interferon-Free Hepatitis C Virus Therapy: Implications for the Innate Immune Response.
- Response-Guided Therapy in Patients with Genotype 1 HCV: Current Status and Future Prospects.
- Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
- Patient-reported outcomes in chronic hepatitis C patients with Cirrhosis treated with sofosbuvir-containing regimens.
- A Randomized, Placebo-Controlled, Single Ascending Dose Study of BMS-791325, a Hepatitis C Virus NS5B Polymerase Inhibitor, in Genotype 1 Infection.
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis.
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for Hepatitis C virus genotype 1 null responders.
- Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study.
- All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV Infection.
- Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.
- Phase 2b trial of interferon-free therapy for Hepatitis C virus genotype 1.
- Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
- Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic Hepatitis C in the REALIZE trial.
- Boceprevir for Chronic HCV Genotype 1 Infection in Patients with Prior Treatment Failure to Peginterferon/Ribavirin, including Prior Null Response.
- Minimal Impact of Sofosbuvir and Ribavirin on Health Related Quality of Life in Chronic Hepatitis C (CH-C).
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 Hepatitis C virus infect...
- Combination of Vaniprevir with Peginterferon and Ribavirin Significantly Increases the Rate of Sustained Viral Response in Treatment-Experienced Patients with Chronic ...
- Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
- Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients with HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy.
- Boceprevir plus peginterferon α-2b/ribavirin in chronic Hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
- All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 Hepatitis C (NUCLEAR).
- Characterization of vaniprevir, a Hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and p...
- Predictors of consent to pharmacogenomics testing in the IDEAL study.
- Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial.
- Adherence to assigned dosing regimen and sustained virological response among chronic Hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2...
- Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options.
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection.
- Treatment of HCV Infection by Targeting MicroRNA.
- Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with Hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, mult...
- Pharmacokinetics, Pharmacodynamics, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor, following Multiple Ascending Doses in Patients with Chronic ...
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 Hepatitis C infection: a rand...
- Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-?2b and ribavirin in patients with chronic Hepatitis C in the SPRINT-1 T...
- Cyclophilin inhibitors for Hepatitis C therapy.
- A Phase 2b Study of Mk-7009 (Vaniprevir) in Patients with Genotype 1 Hcv Infection who have Failed Previous Pegylated Interferon and Ribavirin Treatment.
- A Phase 2a Trial of 12-Week Interferon-Free Therapy with Two Direct-Acting Antivirals (ABT-450/r, ABT-072) and Ribavirin in IL28B C/C Patients with Chronic Hepatitis C...
- Exploratory study of oral combination antiviral therapy for Hepatitis C.
- Limited impact of IL28B genotype on Response rates in telaprevir-treated patients with prior treatment failure.
- Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic Hepatitis C genotype 1 infection.
- The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors.
- Genome-wide association study of interferon-related cytopenia in chronic Hepatitis C patients.
- Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 Hepatitis C virus.
- A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced Liver disease nonresponsive to antiviral therapy.
- Differences in treatment outcome for Hepatitis C among ethnic groups.
- Treatment of chronic Hepatitis C in nonresponders to previous therapy.
- Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic Hepatitis C patients.
- Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) deLivered via a disposable autoinjector device.
- Preliminary study of two antiviral agents for Hepatitis C genotype 1.
- Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with Hepatitis C virus genotype 1.
- Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic Hepatitis C: a prospective, randomized, multicenter, op...
- Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic Hepatitis C pegylated interferon and ribavirin nonresponders.
- Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 Hepatitis C virus infection.
- Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic Hepatitis C.
- Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receivi...
- Boceprevir for previously treated chronic HCV genotype 1 infection.
- Telaprevir for retreatment of HCV infection.
- Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic Hepatitis C virus.
- Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in Hepatitis C patients.
- Evaluation of VCH-759 monotherapy in Hepatitis C infection.
- Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of Hepatitis C infection.
- Seroprevalence of Hepatitis C and associated risk factors among an urban population in Haiti.
- The accuracy of the report of Hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study.
- Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic Hepatitis C virus genotype 1.
- Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic Hepatitis C virus genotype 2 or 3.
- Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 Hepatitis C infe...
- Viral clearance is associated with improved insulin resistance in genotype 1 chronic Hepatitis C but not genotype 2/3.
- Utility of preoperative fiberoptic flexible sigmoidoscopy in the evaluation of patients with suspected gynecologic malignancy.
- A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepat...
Schools
Rush Med Coll Of Rush Univ
Brooke Army Mc
Brooke Army Medical Center
University Of Illinois
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Liver Biopsy
- Liver Surgery
- View All
Conditions Treated
- Abdominal Pain
- Anemia
- Ascites
- Autoimmune Liver Diseases
- View All
Doctors Specialties
- Gastroenterology
- Hepatology
- Transplant Hepatology
Accepted Insurances
Awards
- Fellow (AGAF)
Education
-
San Antonio Uniformed Services Health Education Consortium -
Rush Medical College
Drug Facts
| NPI NUMBER | 1578661716 | |
| NPPES Provider LastName | LAWITZ | |
| NPPES Provider FirstName | ERIC | |
| NPPES Provider ZIPCode | 782151612 | |
| NPPES Provider State | TX | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 956.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 60.0 | |
| Percent Opioid Claims | 6.28 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1578661716 |
| Last Name Of The Provider | LAWITZ |
| First Name Of The Provider | ERIC |
| View All |
Similar Doctors
|
Dr. Fred F. Poordad, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Zarema Singson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Stephen A. Harrison, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Luis J. Acosta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Juan Guerrero, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott T. McNear, DO |
|
Dr. Julio A. Gutierrez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Venkatesan Ranganathan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Pauline Nguyen, ANP |
|
|
Alonzo J. Drummond Jr.
This Doctor is OpenDoctor Recommended.
|